EMEA-002272-PIP01-17
Key facts
Active substance |
Entinostat Polymorph B
|
Therapeutic area |
Oncology
|
Decision number |
P/0087/2018
|
PIP number |
EMEA-002272-PIP01-17
|
Pharmaceutical form(s) |
Film-coated tablet
|
Condition(s) / indication(s) |
Treatment of breast malignant neoplasms
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Syndax Pharmaceuticals, Inc.
Tel. +44(0) 7723045990
|
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|